GeneDx : + Fabric Genomics Presentation

Published: 2025-04-16 10:48:07 ET WGS

A new era in genomic medicine: decentralized AI-powered interpretation with centralized intelligence

GeneDx to acquire Fabric Genomics

April 16, 2025

We envision a world where any genetic disorder is diagnosed quickly to prevent disease progression and ensure long and healthy lives for all.

GeneDx is uncovering genetic diagnoses with an industry- leading interpretation engine

Pay-it-forward data strategy: The snowball effect of data accumulated with every patient tested drives our underlying interpretation platform to get smarter, faster, and more scalable.

Each patient's data strengthens our network of knowledge and helps uncover novel gene-disease connections-enabling more diagnoses for more patients.

4

>750K

exomes & genomes

Decentralized testing with centralized intelligence,

accelerating diagnoses - globally

5

Two companies, one shared goal: earlier diagnoses for all

Largest rare disease database in the US

Proprietary genotypic and phenotypic dataset informing interpretation

State of the art, automated, AI-informed centralized laboratory

Increasing scale and profitability with high throughput and fast turnaround time

AI driven interpretation-as-a-service platform

Cloud based, turnkey, scalable, sequencer-agnostic platform

Proven leadership in scaling complex interpretation services

Domestic and global commercial footprint

Fabric will enable GeneDx's interpretation

Augmenting Fabric's platform with GeneDx's

excellence to reach more patients

dataset will further differentiate its capabilities

6

GeneDx + Fabric Genomics will create a full spectrum of genomics offerings, from GeneDx's centralized lab to decentralized interpretation-as-a-service

Ultimately, this model will accelerate faster and earlier diagnosis of genetic disease, delivering improved outcomes for pati ents and reducing unnecessary costs for healthcare systems in the United States and globally.

CENTRALIZED

DECENTRALIZED

From sample to sequence to report.

GeneDx supports patients and providers with end- to-end exome and genome testing solutions

Sequence locally, interpret globally.

Fabric Genomics' state-of-the-art interpretation platform extracts expert insights from a standard sequencing file

Customers

Customers

Ordering Clinicians

International Clients

Health Systems

Health Systems

Clinical Labs

Clinical Research

7

The acquisition will expand GeneDx's addressable market with multiple scalable revenue streams

NICU Genomic

Genomic Newborn

Decentralization Drives

Platform Economics at

Testing

Screening (gNBS)

Global Commercial

Scale

Expansion

With Fabric Genomics'

GeneDx's leadership in early

Fabric Genomics' cloud-native

Combining GeneDx's

platform integrated into

evidence generation-

platform will enable GeneDx to

proprietary data set with Fabric

clinical workflows across

17,000+ healthy newborns

deliver centralized AI

Genomics' dynamic, recurring

major institutions, GeneDx

sequenced via the

interpretation while complying

revenue-generating platform

can rapidly deploy

GUARDIAN Study-and

with local regulations,

can drive growth through

interpretation infrastructure to

Fabric Genomics' proven

supporting flexible go-to-

software margins and high-

hospitals already sequencing

scalability position the

market strategies and

leverage interpretation

in-house, capturing untapped

combined company to

expanding GeneDx's ability to

services across geographies

demand and opening up

support state and federal

serve global markets with

and clinical use cases

access.

gNBS programs

tailored commercial models

8

Combining GeneDx and Fabric Genomics will unlock leverage within both

companies

Suite of Solutions

Additional Data

Growth International

Synergies Markets

NICU

Amplification

Diversified

Revenue Model

Operating

Cost Expenses

Synergies

Optimizing

Operations

9

Terms of the Transaction

Purchase price of $33 million upfront with total consideration to reach up to a potential $51 million in the aggregate, payable as follows:

$33 million in cash at closing (subject to customary adjustments for cash, debt, transaction expenses and working capital);

Up to a maximum of $10.5 million upon achievement of certain revenue target gross margin targets for the Fabric Genomics business in FY2025

Up to a maximum of $7.5 million upon achievement of certain revenue target and gross margin targets for the Fabric Genomics business in FY2026

Milestone payments for FY 2025 and FY 2026 may be satisfied through cash, shares of GeneDx stock (based on an agreed value as of the signing) or a combination of the two, at GeneDx's sole discretion

10

Healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential - both for better clinical outcomes and for saving the healthcare system valuable dollars.

Together, GeneDx and Fabric Genomics are positioned to transform access to genomic testing globally, driving improved outcomes on an even larger scale.

11

Disclaimer

Genedx Holdings Corp. published this content on April 16, 2025, and is solely responsible for the information contained herein. Distributed via , unedited and unaltered, on April 16, 2025 at 14:47 UTC.